JNPMedi Completes Series A Funding Round of 14 Billion KRW

[Asia Economy Reporter Lee Gwan-ju] Medical data platform company J&P Medi announced on the 22nd that it has completed a Series A investment round worth 14 billion KRW. This comes 10 months after receiving a 2 billion KRW seed investment in January of this year, bringing the total accumulated investment to 16 billion KRW.

This Series A funding was led by Pavilion Capital, the growth investment subsidiary of Temasek, Singapore's largest sovereign wealth fund. Early investors including Kakao Ventures, Murex Partners, AJU IB Investment, and Gentium Partners all participated in the follow-up investment.

Founded in July 2020, J&P Medi is a leading company in IT-based clinical trial data solution platforms utilizing cloud and blockchain technologies. The clinical trial sector, which has lagged behind other fields in digitalization, is considered a promising industry with high demand for innovative technologies and abundant growth potential.

J&P Medi has independently developed the 'Maven Clinical Cloud' solution, a clinical trial data management platform applicable across various medical fields such as pharmaceuticals, biotechnology, digital therapeutics, and digital medical devices.

Jung Kwon-ho, CEO of J&P Medi, stated, "We have been dedicating company-wide efforts to establish the technical and service foundations necessary to achieve innovation in digital clinical trials. Moving forward, we will introduce an all-in-one ecosystem that covers everything related to digital clinical trials, based on world-class technology."

This content was produced with the assistance of AI translation services.